CYRAMZA® (ramucirumab): Indications for Use

Detailed Information

Ramucirumab is a human VEGFR-2 antagonist indicated

• as a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or GEJ adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy

• in combination with erlotinib, for first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations

• in combination with docetaxel, for treatment of metastatic NSCLC with disease progression on or after platinum-based chemotherapy

  • patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving ramucirumab

• in combination with FOLFIRI, for the treatment of mCRC with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine, and

• as a single agent, for the treatment of HCC in patients who have an AFP ≥400 ng/mL and have been treated with sorafenib.¹

Enclosed Prescribing Information

CYRAMZA® (ramucirumab) injection, for intravenous use, Lilly

Reference

1. Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.

Glossary

AFP = alpha-fetoprotein

ALK = anaplastic lymphoma kinase 

EGFR = epidermal growth factor receptor

FDA = Food and Drug Administration 

FOLFIRI = irinotecan, folinic acid, and 5-fluorouracil

GEJ = gastroesophageal junction

HCC = hepatocellular carcinoma

mCRC = metastatic colorectal cancer

NSCLC = non-small cell lung cancer

VEGFR-2 = vascular endothelial growth factor receptor 2